FHTX/ 12/03/2025 · 5:41 PM Stifel Bullish on Foghorn Therapeutics Stock Stifel starts Foghorn Therapeutics coverage with Buy rating and $12 target. Lead drug FHD-909 partnership with Eli Lilly expected to launch in 2030 with strong sales potential.